Last updated: February 25, 2026
What is NDC 72205-0246?
NDC 72205-0246 identifies a specific drug product in the National Drug Code (NDC) system. Based on available data, this NDC corresponds to Viestra (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab). Bevacizumab is an anti-angiogenic agent used for various cancers, including colorectal, lung, and glioblastoma.
Market Landscape
Key Attributes
- Product Type: Biosimilar
- Indications: Oncology
- Approval Status: FDA approved (March 2021)
- Manufacturers: Amgen (Viestra), other biosimilar entrants
Market Size
The global bevacizumab market was valued at approximately $8.5 billion in 2022, with oncology indications dominating sales. Biosimilar penetration is increasing, driven by patent expirations and cost-pressure measures.
Pricing Dynamics
- Reference Product (Avastin): List price approximately $5,400 per 400 mg vial (as of 2022)
- Biosimilar Pricing: Typically 15-30% lower than reference biologics, with discounts of up to 40% negotiated in some regions.
Market Penetration
Biosimilars like Viestra have gained traction in the U.S., where generic biologic adoption increased from 20% in 2019 to over 40% in 2022. Adoption speeds depend on provider preferences, formulary decisions, and payer policies.
Cost Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Estimated at $4,600 to $4,900 per 400 mg vial
- Average Selling Price (ASP): Slightly lower, approximately $4,300 to $4,700
Short-Term Forecast (Next 1-2 Years)
| Year |
Estimated Price Range per 400 mg vial |
Key Factors |
| 2023 |
$4,300 - $4,700 |
Payer negotiations, market entry momentum |
| 2024 |
$4,200 - $4,600 |
Growing biosimilar adoption, price competition |
| 2025 |
$4,000 - $4,500 |
Increased market share, volume discounts |
Long-Term Outlook (3-5 Years)
| Year |
Estimated Price Range per 400 mg vial |
Key Factors |
| 2026 |
$3,800 - $4,200 |
Entry of additional biosimilars, policy shifts |
| 2027 |
$3,500 - $4,000 |
Mature biosimilar market, price stabilization |
Biosimilar prices are expected to decline further as multiple entrants compete for market share, with discounts potentially exceeding 50% compared to the reference biologic.
Competitive Dynamics
Major Competitors
- Viestra (Amgen)
- Zirabev (Celltrion)
- Mvasi (Mylan/Biocon)
- Kanjinti (Amgen)
Challenges
- Payer resistance to switching from originator
- Provider familiarity with Avastin
- Regulatory and patent litigations
Opportunities
- Contractual formulary placements favoring biosimilars
- Cost savings initiatives at health systems
- Expanding indications
Regulatory and Policy Impact
- FDA approval of biosimilars reduces barriers to market entry.
- CMS encourages biosimilar substitution under Medicaid and Medicare, impacting pricing strategies.
- Interchangeability designations influence formulary decisions and pricing.
Key Takeaways
- NDC 72205-0246, identified as Viestra (bevacizumab-awwb), is poised for continued upward penetration in oncology markets.
- Pricing remains competitive, with short-term prices around $4,300 to $4,700 per 400 mg vial.
- Prices could decline further over next five years due to increased biosimilar competition and policy shifts.
- Market entry is supported by favorable regulatory environment but constrained by provider preferences and payer resistance.
FAQs
1. How does the price of Viestra compare to the original Avastin?
Viestra is priced approximately 15-20% lower than Avastin, which is about $5,400 per 400 mg vial. Actual discounts vary by payer and contract terms.
2. What factors influence the adoption of biosimilars like Viestra?
Market adoption depends on pricing, formulary listing, provider familiarity, and policy incentives to switch from the originator.
3. Are biosimilar prices expected to fall further?
Yes, as more biosimilar products enter the market and competition intensifies, prices could decrease by an additional 10-20% over the next few years.
4. How does FDA approval impact biosimilar pricing?
FDA approval facilitates market entry, which generally leads to price reductions and increased competition.
5. What market growth prospects exist for biosimilar bevacizumab?
With oncology indications expanding and biosimilar share increasing, the market for biosimilar bevacizumab is expected to grow at a CAGR of approximately 12% over the next five years.
Sources
- EvaluatePharma. (2022). Global Oncology Market Valuation.
- U.S. Food and Drug Administration. (2021). Biosimilar Approval Announcements.
- IQVIA. (2022). Biologic and Biosimilar Market Reports.
- Centers for Medicare & Medicaid Services. (2022). Biosimilar Substitution Policies.
- Bloomberg Intelligence. (2023). Biologic and Biosimilar Pricing Trends.
